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1. Introduction 
Bone is the preferred site for breast cancer metastasis, which leads to altered mineral 
metabolism, disruption of bone architecture, and considerable pain burden. Prior to homing 
to the bone, the primary breast tumour releases soluble factors that lead to the creation of a 
pre-metastatic niche in the bone, which then serves to attract and maintain invading breast 
cancer cells. Breast cancer cells actively influence resident bone cells, altering both the action 
of and cross-talk between bone forming osteoblasts and bone-destroying osteoclasts. Breast 
cancer cells inhibit osteoblast differentiation and prevent them from creating and 
mineralizing new bone. Immature osteoblasts act as part of a hematopoietic stem cell niche 
and provide an attachment site for breast cancer cells. Breast cancer cells also produce 
factors, such as parathyroid hormone-related protein (PTHrP), which induce osteoblasts to 
stimulate the production of the pro-resorptive cytokine RANKL and to inhibit the 
production of RANKL inhibitor, OPG. RANKL, together with other osteoclastogenic factors 
released from breast cancer cells, promotes the fusion and differentiation of osteoclasts, 
resulting in bone destruction. As a result of bone resorption, growth factors stored in the 
bone matrix, such as TGF, are released and can further stimulate the proliferation and 
survival of tumour cells. Thus, the complex interactions between breast cancer cells and the 
bone microenvironment underlie the homing of the breast cancer to bone and the 
subsequent progression of osteolytic lesions. Current therapeutics against bone metastases 
aim to prevent osteoclastic bone resorption by blocking osteoclast differentiation or 
stimulating their apoptosis. The osteoblast provides a valuable potential target, as a source 
of osteoclastic differentiation factors, and a platform for cancer cell attachment. Recent 
results from basic and clinical research provide new targets to prevent the interactions 
between breast cancer cells and the bone microenvironment at different stages of the 
metastatic cascade.  
2. Chapter outline 
 Physiological regulation of breast and bone 
 Breast Growth and Development 
- Interactions of normal breast tissue with bone 
- Breast carcinoma 
 Bone Microenvironment 
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- Bone structure and composition 
- Bone functions 
- Osteoclasts, osteoblasts and osteocytes: origins, differentiation, function, 
physiology, pathology 
- Bone marrow and hematopoietic stem cell niche 
- Bone cell communications during normal bone remodelling 
 Homing of breast cancer cells to bone 
 Creation of pre-metastatic niche 
 Migration of breast cancer cells to bone 
 Attachment proteins between breast cancer cells and the bone  
 Osteomimicry 
 Establishing of a metastatic tumor in the bone microenvironment 
 Interactions with osteoblasts 
- Inhibition of osteoblasts by breast cancer cells  
- Contribution of osteoblasts to the creation of an osteolytic environment  
- Role of osteoblasts in supporting breast cancer cells 
 Interactions with osteoclasts 
- Stimulation of osteoclasts by breast cancer cells  
- Role of osteoclasts in supporting breast cancer cells 
 Therapeutic targets in the bone microenvironment 
 Conclusions 
 References 
3. Physiological regulation of breast and bone 
3.1 Breast growth and development 
Interactions of normal breast tissue with bone 
The interactions of normal breast tissue with bone arise during childbearing and breastfeeding. 
A normal human fetus needs approximately 30 g of calcium to mineralize its skeleton during 
gestation (1), that leads to significant changes in calcium homeostasis during pregnancy, 
including adjustments in levels of parathyroid hormone (PTH), calcitonin and 1,25 dihydroxy-
vitamin D [1,25[OH]D] (2). These hormones exhibit their effects through three main target 
tissues – the intestines, kidneys and bone (3). Parathyroid hormone related peptide (PTHrP) is 
a hormone closely related to PTH, but which is produced by local tissues, such as breast, and is 
important for its differentiation (4). In addition to its role in local tissue development, PTHrP 
can substitute for PTH in the tissues expressing their common receptor, and thus participate in 
calcium homeostasis by elevating 1,25(OH)D and suppressing PTH, regulating placental 
calcium transport, and affecting bone resorption in the maternal skeleton (3). The regulation of 
calcium homeostasis by the lactating mammary gland may be of critical importance, since 
nursing humans secrete 300-400 mg of calcium into milk each day (5). The hormonal balance 
changes again during lactation, with still-reduced PTH levels, but normalized calcitonin and 
1,25(OH)D, and increased PTHrP (2). During this time, increased prolactin concentrations 
allow for the release of breast milk, and also act to enhance bone turnover (6,7). Suckling 
stimulates prolactin secretion and inhibits GnRH production, both of which reduce estradiol 
levels, leading to bone resorption (8). Bone resorption has been shown to increase during 
lactation, and bone formation to decrease, resulting in a loss of 5-10% of trabecular mineral 
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content per month (9). Lactation-induced fragility fractures have been reported as a result, but 
are not common (10). Of interest, other important molecular mediators for the developing of 
lactating mammary gland are receptor activator of nuclear factorB (RANK) and its ligand 
RANKL, which are better known for their key role in regulating the formation of osteoclasts. 
Expression of RANKL in the mammary epithelium is induced by hormones increased during 
pregnancy, such as prolactin, progesterone, and PTHrP, and mice lacking RANKL or RANK 
cannot form lobuloalveolar mammary gland structures, resulting in complete inability to 
develop a lactating mammary gland (11). Thus, normal breast tissue can interact with bone 
through a system of hormonal regulators that are important during lactation, and it expresses 
molecular machinery that employs the same mediators to perform locally distinct functions 
(Figure 1).  
 
 
Fig. 1. Physiological interactions between the functions of breast and bone. Lactation 
involves secretion of large amounts of calcium. Bone is a key participant in calcium 
homeostasis. PTH is reduced during lactation while PTHrP production by the breast tissue 
is increased. Suckling stimulates prolactin secretion and inhibits GnRH production, both of 
which reduce estradiol levels, leading to bone resorption. Prolactin and PTHrP induce 
breast expression of RANKL, necessary for normal lactating mammary gland function. In 
the bone tissue, osteoblast-produced RANKL is key regulator of osteoclastogenesis. 
Breast carcinoma 
Breast carcinomas may arise from the inner lining of the milk ducts or from the lobules, 
known, respectively, as ductal carcinomas or lobular carcinomas (12). Once a tumour 
exceeds 1-2 mm in diameter, it requires extensive vascularization in order to survive (13), 
but the speed of cancer growth often exceeds its capability to form normal vascular 
organization. Poor angiogenesis results in an under-vascularized microenvironment, which 
leads to hypoxia, acidic pH and nutrient depletion in the tumour (14). Some cancer cells may 
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develop the ability to detach from the primary tumour and invade other areas to form 
secondary tumours, in a process called metastasis. Breast cancer cells favour regional lymph 
nodes as well as the liver, lungs, brain and bone as sites of metastasis (15). The metastatic 
process occurs in a complex series of interrelated steps. An epithelial-to-mesenchymal-
transition (EMT) may occur whereby epithelial breast cancer cells take on a mesenchymal 
phenotype of reduced attachment to neighbouring cells and increased migratory capabilities 
(16). This may assist in their intravasation process, where the cell breaks through the 
epithelium into a blood vessel (17). From here, the cell migrates to a distant site, which is 
driven by chemotaxis and the communication between the cancer cell and a secondary site 
where it aims to establish (18-20). Instead of combating cancer cells, tumor-associated 
macrophages and T-cells may assist in the survival and dissemination of cancer cells by 
mitigating the immune response and promoting cancer progression (21,22). When the cell 
has reached its destination, it will then undergo extravasation to exit the blood vessel and 
establish in a new tissue (23). Bone is a preferred site for breast cancer metastases, therefore 
specific interactions are likely to establish between breast cancer cells and bone cells. 
3.2 Bone microenvironment 
Bone is a dynamic tissue that provides support and protection for organs and maintains 
body mineral homeostasis. All 213 bones are constantly remodelled by the coordinated 
action of specialized bone cells—osteoclasts that destroy bone and osteoblasts that build 
bone. Bone remodelling contributes to the many functions that bones provide and occurs at 
different rates in different areas. Higher rates of bone turnover are observed in trabecular 
bone compared to cortical bone (24), and at bone sites adjacent to actively hematopoietic 
bone marrow in the axial skeleton, where bone metastases also commonly occur (25). High 
bone turnover has been found to correlate to poor prognosis in patients with bone 
metastases (26), and prostate cancer cells have been shown to preferentially metastasize to 
sites of active bone turnover (27), making bone homeostasis an essential part of 
understanding cancer progression.  
Structure  
The adult skeleton is composed of 80% solid and dense cortical bone, surrounding the 
remaining 20% trabecular bone, a network of plates and rods through the bone marrow (28). 
Bone is composed of an organic phase of extracellular matrix containing collagen-1 triple-
helical chains and non-collagenous proteins, and mineral phase of hydroxyapatite crystals 
[Ca10(PO4)6(OH)2]. Osteogenesis occurs by two distinct mechanisms – endochondral 
ossification, and intramembranous bone formation. Endochondral ossification occurs in 
most bones of mesodermal origin that form the axial skeleton, including long bones, skull, 
ribs and vertebrae, and involves the formation of initial mineralized cartilage template, 
which is first degraded by osteoclasts and then replaced with bone matrix by osteoblasts 
(29,30). Intramembranous ossification occurs in the flat bones and the mandible, maxilla and 
clavicle, where an ossification centre is created when mesenchymal stem cells condense, and 
directly differentiate into bone-forming osteoblasts (31).  
Functions  
The mechanical functions of bone are probably their best recognized. Bones protect internal 
organs from damage and support the structure of the body. Bones provide anchorage for 
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muscles, ligaments and tendons to allow movement in three-dimensional space. Hearing is 
also attributed to the mechanics of bones, with several of the body’s smallest bones involved 
in the transmission of sound in the ear. Bone is the body’s major reservoir of calcium, 
storing approximately 99% of it in the bone’s mineral phase. Plasma calcium levels are 
strictly regulated in the range of 2.2-2.6 mmol/L total calcium. Such regulation is achieved 
by regulating calcium exchange with the environment through the kidney and intestine, 
and, in the absence or insufficiency of environmental sources, by regulating calcium 
exchange between plasma and bone through osteoblastic bone formation and osteoclastic 
bone destruction (32). The coordination of calcium fluxes is achived through complex 
hormonal regulation. Parathyroid hormone and 1,25 dihydroxy-vitamin D act to increase 
calcium by increasing calcium reabsorption from the kidneys and small intestine, 
respectively, and both act by enhancing the mobilization of calcium from bone through 
resorption (33). Calcitonin acts to reduce blood calcium by suppressing renal calcium 
reabsorption and inhibiting the mobilization from bone by preventing bone resorption (34). 
The combined work of these systems ensures that hypo- or hyper-calcemia is corrected, and 
ingested calcium is stored or eliminated as waste.  
Bone tissue also interacts with other functionally diverse systems in the body. The endosteal 
surface of the medullary cavity of bones houses the haematopoietic stem cell niche, the 
specific location where blood stem cells best differentiate. Osteoblasts are well known to 
support the haematopoietic stem cell niche directly (35), and haematopoietic cells in turn 
regulate osteogenesis (36). Adipocyte-derived leptin regulates both appetite and bone mass 
accrual (37), and osteoblast-derived osteocalcin affects insulin secretion and sensitivity, as 
well as energy expenditure (38,39). It has most recently been shown that the skeleton 
regulates male fertility through osteocalcin (40), extending the breadth of bone’s influence 
into reproduction as well.  
Bone cells 
The three cell types critical to bone’s structure and function are the bone-resorbing 
osteoclast, the bone forming osteoblast, and the mechanosensory osteocyte. These cells work 
in concert to build bones, maintain mechanically sound bone tissue by replacing it on 
average every 10 years, and repair bones in the incidence of trauma.  
Osteoclasts: The destruction of bone, both physiological in the case of morphogenesis and 
replacing old or damaged bone, and pathological in the case of osteolytic diseases such as 
osteoporosis, breast cancer metastasis to bone and rheumatoid arthritis, occurs through the 
activity of the osteoclast. Osteoclasts are cells of hematopoietic origin. The key molecular 
mediators of osteoclast formation from monocytic precursors are macrophage colony-
stimulating factor (M-SCF) acting through its receptor c-fms, and RANKL which binds to its 
receptor RANK (41-43). Osteoprotegerin (OPG) is the high affinity decoy receptor for 
RANKL and is able to prevent osteoclast differentiation by inhibiting RANK-RANKL 
interactions (44). RANKL binding to RANK in the presence of M-CSF induces the 
recruitment of adaptor molecules including TRAF6 by RANK (45), resulting in the 
activation of transcription factor NFB. One of the early targets of NFB is another 
transcription factor essential for osteoclastogenesis, nuclear factor of activated T-cells c1 
(NFATc1), which later undergoes auto-amplification with the assistance of an activator 
protein-1 complex containing c-Fos (46-48). NFATc1 nuclear localization is regulated by 
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calcium signalling, which also activates calmodulin-dependent kinase, critical for further 
osteoclast differentiation (49). These events lead to the expression of osteoclast-specific 
genes including tartrate-resistant acid phosphatase (TRAP), cathepsin K, and b3 integrin 
(50), which are important for the degradation of bone tissue. Osteoclasts resorb bone by 
creating a unique microenvironment localized between this cell and bone tissue. Osteoclasts 
first recognize and bind to the bone matrix with integrin receptors 1 that bind collagen, 
fibronectin and laminin, and v3 that binds osteopontin and bone sialoprotein (51). This 
border forms a sealing zone over the area of bone to be resorbed, and the polarization of 
osteoclasts results in the formation of a ruffled border between the osteoclast and matrix 
(52). Targeted secretion of H+ ions through the ruffled border H+ ATPase, accompanied by 
movement of Cl- through chloride channels, acidifies the sealed space to a pH of 
approximately 4.5 (53,54), resulting in dissolution of the mineral phase of bone, and 
proteolytic enzymes cathepsin K and matrix metalloproteinase-9 (MMP-9) are released and 
activated to digest the organic matrix (55).  
Osteoblasts: Osteoblasts are differentiated from the mesenchymal stem cells (MSC) that can 
also give rise to progenitors of myoblasts, adipocytes and chondrocytes (56). Commitment 
of MSC to become osteoprogenitors results in the upregulation of receptors for hormones, 
cytokines and growth factors, including PTH, prostaglandin, interleukin-11, insulin-like 
growth factor-1 and transforming growth factor- (57). Next, osteoprogenitor cells 
differentiate into preosteoblasts, cells that exhibit limited proliferation and start to express 
extracellular matrix proteins, such as collagen type I, bone sialoprotein and osteopontin. 
Preosteoblasts are also active in the production of pro-resorptive cytokine RANKL (58). 
Finally, mature osteoblasts do not proliferative, but actively produce and secrete collagen 
type I, bone sialoprotein and osteopontin as well as osteocalcin. In addition, mature 
osteoblasts switch to produce the RANKL inhibitor, OPG (58). Osteoblastogenesis 
commitment is driven by the downstream activities of Wingless-ints (Wnt) singling, the 
closely associated Hedgehog signalling pathway (Sonic Hedgehog, Indian Hedgehog) and 
bone morphogenetic proteins (BMPs), which determine where mesenchymal stem cells 
condense during embryonic patterning and cross-talk to induce osteoblast differentiation 
(59,60). Another developmentally important pathway, Notch signalling, has been shown to 
negatively regulate osteoblast differentiation (61-63). Important signalling events during 
osteoblast differentiation include the activation of the runt-related transcription factor 2 
(Runx2) transcription factor, which regulates the expression of the zinc finger-containing 
transcription factor Osterix (64). Osterix interacts with nuclear factor for activated T cells 2 
(NFATc2), and in collaboration, controls the transcription of osteoblastic target genes 
osteocalcin, osteopontin, osteonectin and collagen-1 (65,66). Osteoblasts anchor to newly 
formed bone matrix by cadherin-11 and N-cadherin, and secrete type 1 collagen and non-
collagenous matrix proteins (57). The osteoblasts then regulate the subsequent 
mineralization of extracellular matrix (67-69).  
Osteocytes: While each cell type is essential for the maintenance of bone homeostasis, 
osteocytes are the most populous and account for over 95% of all cells in the skeleton, 
covering 94% of all bone surface (70). Osteocytes are differentiated from osteoblasts 
embedded in the bone matrix. During differentiation, the osteocyte cell body size decreases, 
and the number of long dendrite-like cell processes increases and they extend, connecting 
the cell with other osteocytes (70,71). Osteocyte-specific genes are activated, including 
phosphate-regulating gene with homologies to endopeptidases on the X chromosome 
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(PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 (DMP1), 
and fibroblast growth factor-23 (FGF23) (72,73). Osteocyte networks in the bone tissue are 
implicated in regulating the maintenance and mineralization of bone tissue (70,74), through 
expression of sclerostin, a negative regulator of bone formation (75), as well as in sensing 
mechanical load in part through sheer stress generated by interstitial fluid moving through 
the lacuno-canalicular network (76). It has also been suggested that osteocytes participate in 
mineral homeostasis by resorbing the lacunar walls in which they are embedded (77-79).  
Communication between bone cells during normal bone remodelling 
Osteoblasts, osteoclasts and osteocytes must work in concert to maintain bone homeostasis 
(Figure 2). In normal bone physiology, the osteoclast will resorb worn or damaged bone, 
and then the osteoblast will form new bone in its place. The best studied example of the 
crosstalk between bone cells involves the RANK-RANKL-OPG triangle, where osteoblasts 
and osteocytes produce RANKL to promote osteoclast differentiation and survival, and 
OPG to prevent it, while osteoclasts express RANK, allowing them to respond to these 
regulatory cues. Many hormonal regulators of bone remodelling, such as PTH and estrogen, 
were demonstrated to act through changing the ratio of RANKL and OPG expression by 
osteoblasts (80). Interestingly, production of RANKL and OPG by osteoblasts is also 
regulated by their developmental stage, with immature osteoblasts producing more RANKL 
and mature osteoblasts produce more OPG, (58). Osteocytes also, at least in part, affect 
osteoclastogenesis through production of RANKL, which is induced in mechanically-
stimulated osteocytes (81). Osteoclasts are in turn able to influence osteoblast activity. The 
concept of osteoclast-mediated osteoblastogenesis arose from the finding that 97% of new 
bone formation occurs in resorption pits (82). Several studies where osteoclasts have been 
genetically altered to have impaired function demonstrated diminished bone formation (83), 
and studies have begun to find mediators of this reversal coupling. Cardiotrophin-1 is 
among the first identified, and is expressed by osteoclasts and increases osteoblast activity 
(84). Sphingosine-1-phosphate has been shown to act earlier and induce osteoblast precursor 
recruitment and subsequent mature cell survival (85). Ephrin-B2/EphB4 bidirectional 
signaling between osteoclasts and osteoblasts, has also been identified as a key mediator of 
contact-dependent communication. Forward signalling by ephrin-B2 on osteoclasts to 
EphB4 on osteoblasts activates bone formation, whereas reverse signalling from EphB4 on 
osteoblasts binding to ephrin-B2 on osteoclasts inhibits osteoclastogenesis (86). Since the 
ability for bone cells to communicate is essential for the maintenance of bone homeostasis, it 
can be anticipated that disruptions in these the complex networks would lead to profound 
consequences. Indeed, the RANKL/OPG ratio represents one of the key mediators of 
pathological bone destruction (87).  
4. Homing of breast cancer cells to bone 
4.1 Creation of the pre-metastatic niche 
Recent evidence has led to the idea that the bone marrow supports a pre-metastatic niche - a 
site that receives signals from the primary tumour mass before dissemination, and changes 
the landscape of the target tissue to be conducive to tumour growth. It has been shown in 
mice treated with medium conditioned by tumour cells of different origin, the potential to 
home to different organs of subsequently injected cancer cells can be altered (88). In 
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particular, in bone, bone marrow derived hematopoietic stem cells have been implicated in 
mediating the establishment of pre-metastatic niche (19,88). Molecular mediators such as 
vascular endothelial growth factor (VEGF) receptor 1 (VEGFR1) and integrin ┙4┚1 have 
been implicated in this process. VEGFR1 positive haematopoietic progenitor cells are 
recruited to sites of future metastasis (88). VEGF receptors are expressed by breast cancer 
cells as well as osteoclasts and osteoclast precursors, and VEGF expression correlates to 
increased tumour size and grade in humans (89). In addition, we have shown that breast 
cancer cells secrete factors that support the subsequent attachment of breast cancer cells 
acting at least in part through -secretase-mediated Notch signalling (20). 
 
 
Fig. 2. Cell-cell interactions in the bone microenvironment. Osteoclast differentiation from 
monocytic precursors is induced by M-CSF, RANKL produced by osteoblastic cells. 
Osteoblasts are derived from mesenchymal stem cells through Wnt and BMP signalling 
pathways. Osteoblasts and osteoclasts communicate through osteoblast-derived 
RANKL/OPG and bidirectional Ephrin-B2/EphB4 signalling. Haematopoietic stem cells 
(HSC) support osteoblasts in the HSC niche through BMPs, while osteoblasts support HSCs 
through upregulated Notch signalling through Jagged-1. Osteoclasts cleave SDF-1 to 
mobilize HSCs from the endosteal niche. 
4.2 Migration of breast cancer cells to bone 
Breast cancer cells express receptors that direct their movement towards fertile sites where 
they may establish into secondary tumors. These proteins are generally expressed in normal 
cells, and are often involved in developmental pathways. Several chemokines have been 
suggested to be released from the bone microenvironment, implicating chemoattraction 
through G-protein-coupled chemokine receptors in driving the movement of tumour cells 
towards bone (90). Interactions between stromal-derived factor-1 (SDF-1) and CXCR4 are 
essential for the correct localization of lymphocytes and haematopoietic cells in 
physiological states. Breast cancer cells express higher levels of CXCR4 compared to normal 
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breast tissue (15), and SDF-1 is strongly expressed in lung, liver, bone marrow and lymph 
nodes, the primary sites of secondary breast tumours, leading to the identification of the role 
of the SDF-1/CXCR4 in promoting breast cancer metastasis to bone (91). In addition to 
directional migration, chemokines have been shown to promote cancer cell survival, 
proliferation, and adhesion (92). In keeping, the inhibition of CXCR4 limited breast cancer 
metastases in mice (93), and the overexpression of CXCR4 indicates poor prognosis in both 
human and murine breast cancer (92,94). Another chemokine implicated in metastases of 
breast cancer cells expressing high levels of CCL21, is CCR7 that is expressed highly in 
metastatic sites, such as lymph nodes (15). Since haematopoietic stem cells (HSCs) use these 
chemokine and receptor interactions to home to the HSC niche in the bone marrow, it has 
been suggested that cancer cells use this same mechanism to parasitize these 
microenvironments and harvest the resources of HSCs (95). Another pertinent means of 
cancer cell migration towards bone relies on the cancer cell expression of RANK (96), which 
mediates directional migration of breast, melanoma and prostate cancer cells towards 
RANKL, produced in bone by osteoblasts (97,98).  
Breast cancer cells may also stimulate the action of matrix metalloproteinases that support 
cancer cell migration and invasion. The murine orthologue of Glycogen Nonmetastatic 
Melanoma Protein B (GPNMB) is called osteoactivin and has been identified as a key 
modulator of osteolysis. Its forced expression leads to increased tumour grade and 
enhanced bone metastasis by upregulated MMP3 through ERK signaling (99,100). 
Furthermore, GPNMB was identified as a poor prognostic marker in patients with breast 
cancer (101). Most recently, this group has identified ADAM10 as a sheddase that releases 
osteoactivin from the cell, which induces endothelial cell migration and subsequent 
angiogenesis (102). ADAMTS1 and MMP1 are also tumour-derived metalloproteinases able 
to degrade the matrix. The stimulated action of these enzymes by breast cancer cells 
enhances osteoclast differentiation by suppressing OPG expression, and their expression in 
human samples correlates to a greater incidence of bone metastases (103).  
4.3 Attachment proteins between breast cancer cells and the bone  
Cancer cells express or induce the expression of adhesion molecules that may facilitate their 
interactions with the bone microenvironment. The best studied family of proteins that bind 
cancer cells to bone cells are integrins, heterodimeric transmembrane glycoproteins whose  
and  subunits combine to form 24 known combinations with unique specificity for binding, 
signaling and regulatory mechanisms (104). Integrins have been demonstrated to be 
involved in several stages of cancer dissemination, with highly metastatic cancer cells 
displaying a different integrin profile than cells from the primary tumour (105). Several 
integrins have been shown to interact with extracellular matrix proteins during bone 
metastasis, with the most important being v3, a receptor for osteopontin, fibronectin and 
vitronectin (106). Adhesion molecules engaged between breast cancer cells and bone cells 
may overlap with those that bind haematopoietic stem cells (HSC) to osteoblasts. HSC 
preferentially home to areas with more fibronectin (88). Breast cancer cells can attach to 
fibronectin, in an integrin-dependent manner (107). The interaction of cancer cells with 
fibronectin increases the production of matrix metalloproteinase-2 from fibroblasts to 
facilitate invasion (108). Another molecule involved the adhesion of HSC to the endosteal 
niche is annexin II (95). By serving as an anchor for SDF-1/CXCL12, it has been shown to 
regulate the homing of HSC as well as prostate cancer cells to the HSC niche (109,110). 
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Blocking annexin II or its receptor limited the localization of prostate cancer cells to 
osteoblasts and endothelial cells (111). In keeping, the inhibition of the SDF-1/CXCL12 and 
annexin II signaling was shown to inhibit breast cancer progression (112,113). Bone matrix 
proteins, such as bone sialoprotein (BSP) or osteopontin (OPN) have been shown to exhibit a 
potential to regulate the attachment of breast cancer cells to bone (114). Early reports have 
argued that BSP inhibits breast cancer cell binding to bone cells (115). However, breast 
cancer cells have been shown to express both BSP and OPN, and to upregulate BSP 
expression in pre-osteoblasts through BMP signalling; and OPN was found localized 
between cancer cells and bone cells at sites of metastasis (116,117). Moreover, the expression 
of BSP has been found to correlate with bone metastasis development (118), and OPN 
expression and serum concentrations have been shown to be poor prognosis markers in 
breast cancer patients (119,120). As osteopontin is also a mediator of the hematopoietic stem 
cell niche, directing migration and acting as an adhesion molecule to HSC via 1 integrin 
(121), it represents a potentially valuable therapeutic target against bone metastases.  
4.4 Osteomimicry 
Osteomimicry describes the phenomenon where osteotropic cancer cells express proteins 
and receptors found on bone cells and the bone matrix. It was speculated that such 
measures allow cancer cells to evade the immune system and/or establish in the bone 
microenvironment (122,123). These proteins include but are not limited to osteocalcin, 
osteopontin, alkaline phopsphatase and Runx2 (124). Osteoblast transcription factor Runx2 
is ectopically expressed by breast cancer cells and stimulates their proliferation, motility, 
and invasion through increased MMP9 expression from both cancer cells and osteoblasts 
(125,126). Runx2 has also been shown to regulate TGF-influenced PTHrP levels, as well as 
upregulate Indian hedgehog (127). Breast cancer cells express Hedgehog ligands that 
activate osteopontin expression in osteoclasts, promoting osteoclast maturation and 
resorptive activity through upregulated Cathepsin K and MMP9 (128,129). Of interest, 
expression of anti-resorptive OPG has been demonstrated to correlate with increased bone-
specific homing and colonization potential in breast cancer cells (122), and to promote 
cancer cell survival (130,131). Osteoclastic intergrin v3 (54), has been shown to be 
upregulated in metastatic versus primary tumour cells, and has been identified as a critical 
mediator of breast cancer metastasis to bone (107,132). It is unclear whether cells from the 
primary tumour display osteomimetic features that allow their metastasis to bone, or 
whether secondary tumour cells established in the bone marrow and matrix receive 
environmental factors that give them their osteomimetic features. Regardless, the ability of 
cancer cells to produce many of these factors has been beneficial to thrive in the bone 
microenvironment.  
5. Establishing of a metastatic tumour in the bone microenvironment 
5.1 Interactions of breast cancer cells with osteoblasts 
Inhibition of osteoblasts by breast cancer cells  
Breast cancer metastasis to bone is associated with a reduction in bone formation markers in 
patients with bone metastases (133). In vitro, breast cancer cells have been shown to produce 
soluble factors able to inhibit osteoblast differentiation (20,134), the effect that may be 
mediated at least in part by the dysregulation of Notch and Wnt developmental signalling 
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pathways. Notch signalling is essential in embryogenesis but has distinct roles in bone 
homeostasis, regulating the proliferation of immature osteoblasts (135) and suppressing 
osteoblast differentiation (62,63). Upregulated Notch signalling in breast cancer, through 
ligand Jagged-1, has been shown to correlate with increased bone metastases (136), and 
breast cancer cells have been shown to induce Jagged-1 expression and upregulate Notch 
signalling by osteoblasts (20). Wnt signaling is also a highly conserved developmental 
pathway, well studied in bone and essential for osteoblast and osteoclast differentiation, as 
well as for the production of pro-resorptive cytokine RANKL and anti-resorptive OPG (137). 
Wnt inhibitor DKK-1 has been shown to be upregulated in diseases associated with bone 
destruction, such as osteoarthritis (138), myeloma (139), and potentially in Paget’s disease 
(140). Blocking DKK-1 in a breast cancer metastasis model has also been shown to reverse 
breast cancer-mediated suppression of osteoblast differentiation and reinstate OPG 
expression (141). Breast cancer cells have also been shown to induce osteoblast apoptosis, 
through increased Bax/Bcl-2 ratio and caspase expression in osteoblasts (142,143). In 
addition to preventing the formation of new bone, breast cancer-induced inhibition of 
osteoblast differentiation likely indirectly contributes to the change in production of 
cytokines regulating osteoclast formation and function. 
Contribution of osteoblasts to the creation of an osteolytic environment  
The formation of an osteoclast-supportive microenvironment is critical for the successful 
establishment of an osteolytic lesion during breast cancer metastasis to bone. It has been 
previously shown that an increase in the ratio between a pro-resorptive RANKL and anti-
resorptive OPG is a key change induced by breast cancer cells (reviewed in (144,145)). Since 
osteoblasts are the primary source of both pro-resorptive and anti-resorptive cytokines, they 
represent a critical target for cancer-derived factors. Osteoblast production of RANKL is 
stimulated by tumour-derived PTHrP, Il-8 , Il-6 and Monocyte Chemoattractant Protein 
(MCP-1) (reviewed in (146)). Moreover, under the influence of breast cancer cells, 
undifferentiated osteoblasts express higher levels of RANKL and lower OPG, resulting in an 
increase in osteoblast-mediated osteoclastogenesis (20), an effect that was reversed when 
osteoblastic cultures were treated with the inhibitors of -secretase – an enzyme implicated 
in Notch signalling (20,136). One of the mediators of these changes was shown to be the 
tumour-overexpressed CCN3, that can inhibit osteoblast differentiation and shift the 
RANKL/OPG ratio to favour osteolysis (147). Another osteoblast-produced osteoclastogenic 
factor, MCSF, has also been implicated in breast cancer metastases to bone (148). 
Role of osteoblasts in supporting breast cancer cells 
An emerging area of interest is the role of osteoblasts in supporting the haematopoietic stem 
cell niche and how cancer cells parasitize this relationship. Haematopoiesis occurs on the 
endosteal surface of the bone marrow, where haematopoietic stem cells (HSCs) are 
maintained by the supporting cells, including osteoblasts. The main functions of the 
interaction between these cell types are i) the maintenance of HSC quiescence through 
osteoblast-derived osteopontin, and ii) modification to expand the progenitor population 
through Notch signaling (35,121). Several osteoblast-expressed receptors, cytokines and 
growth factors have been found to regulate an haematopoietic stem cell niche (149,150), 
including PTH/PTHrP receptors and BMPs acting to expand the osteoblast population, and 
Notch ligand Jagged-1 to expand the population of HSCs (35,151). Cancer cells disseminated 
from the primary tumour may also lay dormant for long periods of time before being 
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activated to form metastases (152), so it is plausible that cancer cells harvest resources from 
the HSCs niche to maintain their survival and to induce expansion at the right 
environmental cues.  
5.2 Interactions of breast cancer cells with osteoclasts 
Stimulation of osteoclasts by breast cancer cells  
Breast cancer cells have been found to produce many factors capable of simulating 
osteoclastogenesis, both by inducing RANKL expression by osteoblasts and stromal cells, 
and by producing osteoclastogenic factors themselves. PTHrP was one of the first factors 
identified to be secreted by breast cancer cells and to promote osteolysis through the 
stimulation of RANKL by stromal cells (153). Although the expression of PTHrP in primary 
tumours has been associated with a lower incidence of bone metastasis (154,155), it was 
shown that increased PTHrP expression by cancer cells present in the bone metastatic lesion 
positively correlates with increasing osteoclast activity and subsequent osteolysis (155), 
suggesting that the expression pattern of the cancer cells can change during metastasis, and 
implicating local factors, such as TGF derived from osteoclastic bone resorption in affecting 
metastasizing breast cancer cells. Osteoclastogenesis may also be stimulated by IL-8 secreted 
from breast cancer cells and acting both directly on osteoclasts and through osteoblastic 
RANKL signalling (156,157). Although the mechanisms of IL-8 action are not fully 
understood, the expression of IL-8 correlated with a higher incidence of bone metastasis in 
mice in vivo (158).  
It has also been shown that during differentiation osteoclast precursors may acquire 
sensitivity to cancer-derived factors that are ineffective in inducing osteoclast formation 
from naive monocytes (159). Several signalling pathways in osteoclast precursors have been 
implicated in these effects, including calcium signalling, NFATc1 activation and MAPKs 
ERK1/2 and p38 (159,160). Tumour-produced CCN3 was demonstrated to stimulate 
osteoclast formation from RANKL-primed osteoclast precursors (147). These effects can be 
relevant to the propensity of cancer cells to metastasize to bone sites undergoing active bone 
remodelling, and thus containing increased numbers of RANKL-primed osteoclast 
precursors. At such sites, breast cancer cells can promote further osteoclast formation, and 
can affect the survival of mature osteoclasts, increasing their resorptive capacity. In this 
regard, M-CSF secreted from breast cancer cells was shown to be responsible for the delayed 
apoptosis in osteoclasts (146,161). Anti-apoptotic effects of breast cancer-derived factors 
included PLC-mediated suppression of pro-apoptotic protein BIM, and M-CSF-mediated 
inhibition of caspase cleavage (146).  
Role of osteoclasts in supporting breast cancer cells 
During osteoclastic resorption, the bone matrix components, including many growth factors 
stored in the bone, such as TGF┚, BMPs, IGFs, fibroblast growth factors (FGFs), and platelet-
derived growth factors (PDGF) are released into extracellular space, where they are free to 
act on surrounding cells, including metastasizing cancer cells (162). Matrix released- TGF┚ 
activated by osteoclastic resorption (163), is one of the most commonly studied matrix-
derived growth factors, which was shown to stimulate cancer cell growth, modify cell 
invasion, and affect immune regulation (164,165). Considerable research has linked 
increased TGF-┚ in the microenvironment to the progression of metastasis, with TGF 
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altering both the growth and phenotype of breast cancer cells (166), and increasing their 
expression of CTGF, CXCL11 and PTHrP (167) via Smad and MAPK signalling in breast 
cancer cells (153,168,169). PTHrP increases VEGF production, leading to stimulated 
osteoclastogenesis through the ERK1/2 and p38 signalling pathways (170). TGF also acts 
on other cells present in the bone microenvironment, such as osteoclasts themselves by 
sensitizing them to other breast cancer derived factors (159), through the ERK1/2, p38 and 
c-Jun-NH2 kinase signalling pathways (160,171). In keeping with a key role of TGF in bone 
metastases, pharmacological inhibition of TGF signalling through the T┚RI kinase inhibitor 
SD-208 resulted in decreased bone metastasis and tumour burden, and improved bone 
quality (172). The self-accelerating cycle of osteoclast stimulation by breast cancer cells, 
resulting in release of matrix growth factors due to osteoclastic resorption, leading to further 
stimulation of breast cancer cells and further increase in osteoclastic resorption was coined 
the name of “vicious cycle” (173), underlying the strong rationale for the use of anti-
resorptive drugs for the treatment of cancer metastases to bone.  
6. Therapeutic targets in the bone microenvironment 
The bone microenvironment presents multiple targets for developing therapeutic treatments 
targeting the homing of breast cancer cells to bone, as well as progression of bone metastatic 
lesions (Figure 3). Molecular mediators of critical events underlying the stimulation of bone 
resorption and inhibition of bone formation, as well as tumour supportive environmental 
changes and cellular targets have been explored for their benefits in treatment of osteolytic 
bone metastases.  
Since its discovery, the RANKL pathway has been considered to be of important therapeutic 
value given its role in osteoclastogenesis mediating osteolysis and subsequently discovered 
breast cancer cell migration, underlying pre-metastatic homing. Fully human monoclonal 
antibody against RANKL, Denosumab, was approved for major North American and 
European markets in 2010 for the prevention of osteoporosis and skeletal related events in 
patients with bone metastases from solid tumours. Compared to the most potent osteoclast-
targeting drug in the market, bisphosphonate zoledronic acid, Denosumab treatment further 
delayed the occurrence of the first skeletal related event (SRE), and provided a further 
reduction in bone turnover markers in breast cancer patients (174). In non-metastatic breast 
cancer patients additionally receiving adjuvant aromatase inhibitors, bone mineral density 
gains were greater with Denosumab treatment (175). Bisphosphonate-resistant patients with 
bone metastases from breast or prostate cancer also benefitted from Denosumab treatment, 
with most having normalized serum markers of bone resorption after 13 weeks of treatment 
(176). Although Denosumab proves an effective treatment option, long-term use and toxicity 
data remains unknown.  
DKK-1 was identified as a key mediator of myeloma-induced inhibition of bone formation, 
and was demonstrated to play important role in breast cancer induced inhibition of 
osteoblastogenesis. Neutralizing anti-DKK-1 antibodies have demonstrated significant 
benefits in preclinical studies in mouse models of myeloma-induced bone disease, resulting 
in increased osteoblast numbers, reduced osteoclast numbers and increased bone volume, 
and stimulating interest in further development of this approach (177). Bortezomib, a 
proteasome inhibitor that among other proteins affects DKK-1 and BIM (a pro-apoptotic 
protein that mediates osteoclast apoptosis) (178,179), was shown to inhibit 
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osteoclastogenesis (180) and has been successful in combating the osteolytic effects of 
multiple myeloma (181), making it an attractive candidate for the prevention and treatment 
of breast cancer-induced osteolysis. 
 
Fig. 3. Breast cancer cells alter normal bone homeostasis. Breast cancer cells maintain 
osteoblasts in an immature state and stimulate RANKL production by osteoblasts, while 
inhibiting OPG. Breast cancer cells stimulate osteoclastogenesis directly through TGF M-
CSF and CCN3 production. Increased bone resorption by activated osteoclasts releases 
matrix-derived growth factors TGF, IGF, FGF, PDGF, which act back on breast cancer cells 
to stimulate their growth and survival. 
VEGF represents an interesting target potentially affecting breast cancer cell homing, 
development of pre-metastatic niche and new vasculature formation. Many anti-VEGF 
therapies exist to prevent vascularization of tumours and inhibit their growth (182). There 
have been several hindrances in the progress of this therapy due to drug resistance and 
toxicity (183), and the increased incidence of osteonecrosis of the jaw in combined 
bisphosphonate-antiangiogenic agent therapy (184). Notwithstanding, the use of VEGF-A 
monoclonal antibody Bevacizumab in combination with chemotherapy has proven 
beneficial in reducing breast cancer growth (185) and osteolysis (186). Other targets based on 
the in vitro and in vivo studies, such as TGF, GPNMB, and CXCR4 are being explored in 
preclinical and clinical studies, providing the basis for the next generation of treatments.  
Osteoclasts are commonly targeted therapeutically for osteolytic disease, with one of the 
most widely used drugs being bisphosphonates. Analogs of mineralization-inhibiting 
pyrophosphate (187), bisphosphonates are a class of synthetic compounds composed of two 
phosphate groups covalently linked to carbon with a P-C-P backbone and side groups that 
vary their properties and pharmacokinetics. Bisphosphonates attach selectively to bone and 
induce osteoclast apoptosis when they are ingested during resorption. In osteoporosis 
studies, all bisphosphonates given daily have been shown to reduce osteoporotic vertebral 
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fracture rates by 40-50% (188), and zoledronic acid and risedronate have been shown to 
significantly reduce non-vertebral fracture risk in pivotal trials (189). Bisphosphonates are 
widely used in prevention and treatment of breast cancer metastases to bone, resulting in 
delay and reduction in skeletal related events (190). In addition to their effects on 
osteoclasts, bisphosphonates have been shown to inhibit tumour growth, induce tumour cell 
apoptosis, and stimulate the immune response against tumour cells (191). However, some 
patients do not tolerate bisphosphonates well, and low but significant incidences of 
osteonecrosis of the jaw have been observed in patients that have undergone dental 
extraction procedures while treated with bisphosohonates (192). In addition, significant 
proportion of patients failed to normalize bone resorptive indices in response to 
bisphosphonate treatment (176), demonstrating the need for new therapeutic approaches. 
7. Conclusion 
Breast cancer is the most commonly diagnosed cancer in women, which may lead to bone 
metastasis resulting in altered mineral homeostasis, the disruption of bone 
microarchitecture, pain and pathological fractures. Recent studies have demonstrated that 
breast cancer cells start affecting the bone microenvironment prior to their dissemination 
from the primary tumour by secreting circulating soluble factors that prepare bone for the 
future arrival of metastasizing cancer cells, a process that likely involves mediators of the 
hematopoietic stem cell niche. Multiple mediators of directional migration of breast cancer 
cells have been identified, as well as mediators of breast cancer cells anti-osteoblastic and 
pro-osteoclastic actions. Breast cancer-stimulated RANKL, M-CSF, PTHrP, TGF, GPNMB, 
Runx2 and CXCR4 remain among the most critical mediators of cancer-induced osteoclastic 
bone resorption. Yet, they are not the whole picture, and new players are being identified, 
providing more complex and comprehensive description of the events leading from the 
formation of primary tumour to the establishment of progressive osteolytic bone lesions. 
However, while considering the multitude of molecular mediators, it is important to 
remember the heterogeneity of breast cancer disease in patients, suggesting that treatments 
targeting different molecular mediators should develop in parallel with the testing 
capabilities able to implicate a particular mediator in disease progression in a specific 
patient. An alternative approach is to target the processes and cellular targets similarly 
altered through different molecular mediators. An example of such approach is the clinical 
success of bisphosphonates, which broadly target osteoclast formation and activity. 
Nevertheless, both approaches need to be developed to provide clinicians with the set of 
tools for broad preventive measures, as well as for targeted personalized medicine for non-
responsive or atypical cases.  
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